Scynexis Stock Today
| SCYX Stock | USD 0.73 0.01 1.35% |
PerformanceVery Weak
| Odds Of DistressHigh
|
Scynexis is trading at 0.73 as of the 19th of July 2025; that is 1.35 percent decrease since the beginning of the trading day. The stock's open price was 0.74. Scynexis has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 20th of April 2025 and ending today, the 19th of July 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 2nd of May 2014 | Category Healthcare | Classification Health Care |
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey. Scynexis operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. The company has 39.02 M outstanding shares of which 606.41 K shares are at this time shorted by private and institutional investors with about 3.17 trading days to cover. More on Scynexis
Moving together with Scynexis Stock
Moving against Scynexis Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Scynexis Stock Highlights
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsScynexis can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Scynexis' financial leverage. It provides some insight into what part of Scynexis' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Scynexis (SCYX) is traded on NASDAQ Exchange in USA. It is located in 1 Evertrust Plaza, Jersey City, NJ, United States, 07302-6548 and employs 28 people. Scynexis is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 28.29 M. Scynexis conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 39.02 M outstanding shares of which 606.41 K shares are at this time shorted by private and institutional investors with about 3.17 trading days to cover.
Scynexis currently holds about 96.09 M in cash with (24.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.94, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Scynexis Probability Of Bankruptcy
Ownership AllocationScynexis shows a total of 39.02 Million outstanding shares. About 68.28 % of Scynexis outstanding shares are held by general public with 1.89 (%) owned by insiders and only 29.83 % by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Scynexis Ownership Details
Scynexis Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Northern Trust Corp | 2025-03-31 | 137.6 K | |
| State Street Corp | 2025-03-31 | 120.7 K | |
| Empowered Funds, Llc | 2025-03-31 | 107.3 K | |
| Wealth Effects Llc | 2025-03-31 | 89.5 K | |
| Nierenberg Investment Management Co | 2025-03-31 | 75.6 K | |
| Citadel Advisors Llc | 2025-03-31 | 72.4 K | |
| Ubs Group Ag | 2025-03-31 | 68.9 K | |
| Lpl Financial Corp | 2025-03-31 | 62.9 K | |
| Squarepoint Ops Llc | 2025-03-31 | 37.1 K | |
| Federated Hermes Inc | 2025-03-31 | 2.9 M | |
| Kingdon Capital Management Llc | 2025-03-31 | 2.2 M |
Scynexis Historical Income Statement
Scynexis Stock Against Markets
Scynexis Corporate Management
| Debbie Etchison | Executive Communications | Profile | |
| Scott JD | Chief Secretary | Profile | |
| Marco MD | Pres CEO | Profile | |
| Daniella Gigante | Vice Technology | Profile | |
| Christine MBA | Chief Officer | Profile | |
| David MD | Chief Officer | Profile |
Additional Tools for Scynexis Stock Analysis
When running Scynexis' price analysis, check to measure Scynexis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Scynexis is operating at the current time. Most of Scynexis' value examination focuses on studying past and present price action to predict the probability of Scynexis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Scynexis' price. Additionally, you may evaluate how the addition of Scynexis to your portfolios can decrease your overall portfolio volatility.